Øystein Soug

Chief Executive Officer en Arxx Therapeutics AS .

55 años

Health Technology

Consumer Non-Durables

Consumer Services

Perfil

Øystein Soug is currently the Chief Executive Officer at Arxx Therapeutics AS and a Director at Pharmasum Therapeutics AS.
He previously worked as a Director at Bionor Pharma ASA in 2013, Chief Financial Officer-Russian Division at Orkla ASA, CFO, Head-Finance, Administration & IR at Algeta ASA from 2012 to 2013, and Chief Financial Officer at Circio Holding ASA from 2015 to 2022.
He graduated from the University of St. Gallen in 1997.

Cargos activos de Øystein Soug

Empresas	Cargo	Inicio
Pharmasum Therapeutics AS Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway.	Director/Board Member	-
Arxx Therapeutics AS Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022.	Chief Executive Officer	01/01/2022

Todos los cargos activos de Øystein Soug

Antiguos cargos conocidos de Øystein Soug.

Empresas	Cargo	Fin
CIRCIO HOLDING ASA	Chief Executive Officer	20/10/2021
ORKLA ASA	Director of Finance/CFO	-
Bionor Pharma ASA Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway.	Director/Board Member	-
ALGETA ASA	Director of Finance/CFO	-

Ver el detalle de la experiencia de Øystein Soug.

Formación de Øystein Soug.

University of St. Gallen

Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Øystein Soug.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
ORKLA ASA	Consumer Non-Durables
CIRCIO HOLDING ASA	Health Technology

Empresas privadas	4
Bionor Pharma ASA Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway.	Health Technology
Pharmasum Therapeutics AS Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway.	Health Technology
Arxx Therapeutics AS Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022.	Health Technology
Algeta ASA Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.	Health Technology

Ver las conexiones de la empresa